| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
Purity: ≥98%
| ln Vitro |
It was discovered that SR11237 was unsuccessful at the retinoic acid receptor but could successfully transactivate the chloramphenicol acetyltransferase reporter gene through RXR using a nuclear receptor co-transfection experiment in COS-1 cells [1].
|
|---|---|
| ln Vivo |
On postpartum days 5 to 15, SR11237 (BMS-649) (25 mg/kg; i.p.; daily) induces irregular ossification and premature growth plate closure [2].
|
| Animal Protocol |
Animal/Disease Models: SD (SD (Sprague-Dawley)) rat [2]
Doses: 25 mg/kg Route of Administration: intraperitoneal (ip) injection; one time/day on postpartum days 5 to 15 Experimental Results: Caused ossification and bone morphology disorders in rats, including premature growth plate closure and infiltration of ossified tissue through the central epiphysis. |
| References |
|
| Molecular Formula |
C24H28O4
|
|---|---|
| Molecular Weight |
380.476727485657
|
| Exact Mass |
380.199
|
| Elemental Analysis |
C, 75.76; H, 7.42; O, 16.82
|
| CAS # |
146670-40-8
|
| Related CAS # |
146670-40-8 (SR 11237); 121346-32-5 (SR-33805)
|
| PubChem CID |
127019
|
| Appearance |
White to off-white solid powder
|
| Density |
1.139g/cm3
|
| Boiling Point |
499.9ºC at 760 mmHg
|
| Flash Point |
167.1ºC
|
| Vapour Pressure |
8.16E-11mmHg at 25°C
|
| Index of Refraction |
1.561
|
| LogP |
4.981
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
581
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1CCOC1(C1C=CC(C(=O)O)=CC=1)C1C=CC2=C(C=1)C(C)(C)CCC2(C)C
|
| InChi Key |
ZZUKALQMHNSWTK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H28O4/c1-22(2)11-12-23(3,4)20-15-18(9-10-19(20)22)24(27-13-14-28-24)17-7-5-16(6-8-17)21(25)26/h5-10,15H,11-14H2,1-4H3,(H,25,26)
|
| Chemical Name |
4-(2-(5,6,7,8-Tetrahydro-5,5,8,8,-tetramethyl-2-naphthalenyl)-1,3-dioxolan-2-yl)benzoic acid
|
| Synonyms |
SR 11237; SR11237; SR-11237; BMS 649; BMS-649.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~5 mg/mL (~13.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.31 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6283 mL | 13.1413 mL | 26.2826 mL | |
| 5 mM | 0.5257 mL | 2.6283 mL | 5.2565 mL | |
| 10 mM | 0.2628 mL | 1.3141 mL | 2.6283 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA